Compare Panacea Biotech with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs FRESENIUS KABI ONCO. - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH FRESENIUS KABI ONCO. PANACEA BIOTECH/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 12.1 22.1 54.8% View Chart
P/BV x 2.9 3.1 93.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
FRESENIUS KABI ONCO.
Mar-13
PANACEA BIOTECH/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs364176 206.8%   
Low Rs12979 164.5%   
Sales per share (Unadj.) Rs96.837.7 256.8%  
Earnings per share (Unadj.) Rs-12.45.1 -243.6%  
Cash flow per share (Unadj.) Rs-2.96.7 -42.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs50.442.5 118.5%  
Shares outstanding (eoy) m61.25158.23 38.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.53.4 75.4%   
Avg P/E ratio x-19.925.0 -79.5%  
P/CF ratio (eoy) x-86.418.9 -456.7%  
Price / Book Value ratio x4.93.0 163.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m15,10120,135 75.0%   
No. of employees `0002.51.2 214.2%   
Total wages/salary Rs m1,516703 215.6%   
Avg. sales/employee Rs Th2,401.95,176.2 46.4%   
Avg. wages/employee Rs Th614.2610.4 100.6%   
Avg. net profit/employee Rs Th-307.9699.6 -44.0%   
INCOME DATA
Net Sales Rs m5,9285,963 99.4%  
Other income Rs m8218 457.2%   
Total revenues Rs m6,0105,981 100.5%   
Gross profit Rs m8451,430 59.1%  
Depreciation Rs m585258 226.9%   
Interest Rs m1,006-26 -3,868.5%   
Profit before tax Rs m-6641,216 -54.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m99342 28.8%   
Profit after tax Rs m-760806 -94.3%  
Gross profit margin %14.324.0 59.5%  
Effective tax rate %-14.928.1 -52.8%   
Net profit margin %-12.813.5 -94.9%  
BALANCE SHEET DATA
Current assets Rs m5,6035,102 109.8%   
Current liabilities Rs m6,9102,385 289.7%   
Net working cap to sales %-22.045.6 -48.4%  
Current ratio x0.82.1 37.9%  
Inventory Days Days206150 137.2%  
Debtors Days Days84113 73.9%  
Net fixed assets Rs m9,9415,148 193.1%   
Share capital Rs m61158 38.7%   
"Free" reserves Rs m3,0266,556 46.2%   
Net worth Rs m3,0876,732 45.9%   
Long term debt Rs m5,707952 599.4%   
Total assets Rs m16,07610,388 154.8%  
Interest coverage x0.3-45.8 -0.7%   
Debt to equity ratio x1.80.1 1,307.1%  
Sales to assets ratio x0.40.6 64.2%   
Return on assets %1.57.5 20.4%  
Return on equity %-24.612.0 -205.7%  
Return on capital %3.914.6 26.8%  
Exports to sales %24.074.5 32.3%   
Imports to sales %17.524.8 70.8%   
Exports (fob) Rs m1,4244,441 32.1%   
Imports (cif) Rs m1,0401,477 70.4%   
Fx inflow Rs m1,6005,298 30.2%   
Fx outflow Rs m1,1311,772 63.8%   
Net fx Rs m4693,525 13.3%   
CASH FLOW
From Operations Rs m1,1801,274 92.6%  
From Investments Rs m553-1,204 -45.9%  
From Financial Activity Rs m-1,644-196 838.1%  
Net Cashflow Rs m90-126 -71.0%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 0.6 0.3 200.0%  
FIIs % 1.3 9.6 13.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 9.1 259.3%  
Shareholders   10,259 42,599 24.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 18, 2019 12:57 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS